Many people with diabetes have the earliest stage of diabetic retinopathy, called mild nonproliferative diabetic retinopathy (NPDR), without even knowing it, according to the American Academy of ...

Two large NIH-funded clinical studies have shown promising results that laser photocoagulation therapy prevents vision loss in patients with diabetic retinopathy. Results of the Diabetic Retinopathy ...

Eye injections are the only medication currently available to treat diabetes-related retinopathy. Modern eye injections are not painful and don’t cause many side effects. Diabetic retinopathy affects ...

Diabetic retinopathy is a complication of diabetes that affects vision. Nonproliferative diabetic retinopathy describes the earlier stages of the condition before it progresses into the final and most ...

No, diabetes-related retinopathy is not reversible. But you can slow down progression or stop it from getting worse through diabetes management, eye injections, laser treatment, and more. Diabetic ...

Treating people in the early stages of diabetes-related eye disease may help slow the progression of the condition, but a new study also suggests that it can’t help prevent vision loss in the future.

Glass tried the injections for his advanced disease, but they did not halt his vision loss. So his ophthalmologist tried ...

Disc neovascularization (NVD) was less frequent among patients with proliferative diabetic retinopathy but was associated with more resistance to currently available treatments compared with ...

A team led by UCL scientists has identified a key protein that triggers diabetic retinopathy—a condition caused by high blood ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. PARK CITY, Utah — APX3330, an investigational systemic ...

Diabetic retinopathy involves damage to the eye’s retina due to high blood sugar levels in the body. It is a common complication of diabetes, affecting millions of people with both type 1 and type 2 ...

Q3 2025 Management View CEO Pravin Dugel described 2025 as "a transformative year for Ocular Therapeutix" and highlighted the advancement of two registrational studies in wet AMD, SOL-1 and SOL-R.